Recruiting
Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Sponsor:

AstraZeneca

Code:

NCT06346392

Conditions

Gastric Cancer

Gastroesophageal Junction Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AZD0901

AZD0901

Ramucirumab+ paclitaxel

Paclitaxel

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information